Navigation Links
Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
Date:2/1/2011

HAYWARD, Calif., Feb. 1, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced that it has appointed Dr. Peter Thompson to its Board of Directors. Currently, Dr. Thompson is a venture partner with OrbiMed and is the founder and Managing Director of Strategicon Partners, an investment and management services company. In 2009, Dr. Thompson retired as the Chief Executive Officer and Chairman of Trubion Pharmaceuticals, which he co-founded. He is also the former Vice President and General Manager of Chiron Informatics and held various executive positions at Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year recipient, an inventor on numerous patents, a board-certified internist and oncologist, and was on staff at the National Cancer Institute following his internal medicine training at Yale University.

Dr. Thompson will be succeeding Dr. A. Rachel Leheny, who has informed the company of her decision to resign from the Board of Directors. Dr. Leheny has served as a member of the board since August 2008.  Dr. Thompson will join the Board as a Class II Director and will stand for re-election by the company's stockholders at Anthera's 2011 Annual Meeting.

"Peter is a deeply experienced executive and his addition will offer new insight and perspectives as Anthera advances its late stage pipeline," said Paul Truex, Anthera's President and Chief Executive Officer. "I would like to thank Rachel for her invaluable guidance as a Director, we will miss having her perspective as we move forward."

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Certain statements contained in this press release that refer to future events are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium
2. Dr. Peter J. Pronovost to Join the Board of Directors of Cantel Medical Corp.
3. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
4. Kinetic Systems Appoints Peter M. Maris President & Chief Executive Officer
5. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
6. Accuray Appoints Peter Fine to Board of Directors
7. Codexis Names Peter Strumph SVP, Commercial Operations
8. Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
9. Vermillion Adds Peter S. Roddy to Board and Provides Corporate Update
10. Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing
11. VIVUS Announces Promotion of Peter Tam to President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... the U.S. Food and Drug Administration (FDA) has notified the ... to its Zhejiang, China manufacturing facility ... "The successful clearance of the Warning Letter related to our ... a measure of the progress we have made in our ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... Pekin, IL (PRWEB) , ... June 28, 2017 , ... ... research shows that every 62 minutes, at least one person dies as a direct ... grows, a greater need exists for qualified treatment providers. The iaedp Foundation meets this ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) ... year study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium ... brine-impacted groundwater. As a part of the study, batch adsorption experiments were conducted ...
(Date:6/27/2017)... Fla. (PRWEB) , ... June 27, 2017 , ... ... today announced the appointment of Mike Finnegan to the position of Executive Vice ... years of experience in healthcare technology, telehealth and medical device sales leadership. He ...
(Date:6/27/2017)... ... 27, 2017 , ... The Congressional Budget Office (CBO) projects that the Better ... Patient Protection and Affordable Care Act (ACA), would result in 22 million Americans losing ... law. , More than 20 million Americans have gained health insurance under the ACA, ...
Breaking Medicine News(10 mins):